both beat it to market and Rinvoq also has head-to-head data showing improvement over Dupixent. The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs ...

The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...